Johnson & Johnson (NYSE:JNJ) Holdings Raised by Dodds Wealth LLC

Dodds Wealth LLC grew its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 15.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,576 shares of the company’s stock after purchasing an additional 482 shares during the quarter. Dodds Wealth LLC’s holdings in Johnson & Johnson were worth $593,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of JNJ. Norges Bank bought a new position in shares of Johnson & Johnson during the 4th quarter valued at $4,390,037,000. Raymond James Financial Inc. bought a new position in Johnson & Johnson in the 4th quarter worth $1,339,878,000. GAMMA Investing LLC raised its holdings in Johnson & Johnson by 24,450.4% in the 1st quarter. GAMMA Investing LLC now owns 7,215,367 shares of the company’s stock worth $1,196,596,000 after acquiring an additional 7,185,977 shares during the period. Janus Henderson Group PLC raised its holdings in Johnson & Johnson by 134.5% in the 4th quarter. Janus Henderson Group PLC now owns 7,948,508 shares of the company’s stock worth $1,149,536,000 after acquiring an additional 4,559,147 shares during the period. Finally, Northern Trust Corp raised its holdings in Johnson & Johnson by 12.3% in the 4th quarter. Northern Trust Corp now owns 30,813,175 shares of the company’s stock worth $4,456,201,000 after acquiring an additional 3,363,235 shares during the period. Institutional investors own 69.55% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently commented on the stock. Morgan Stanley lifted their target price on shares of Johnson & Johnson from $164.00 to $169.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 16th. Benchmark upgraded shares of Johnson & Johnson to a “strong-buy” rating in a report on Thursday, April 24th. Bank of America dropped their target price on shares of Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating on the stock in a report on Thursday, April 10th. Wall Street Zen lowered shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Thursday, May 22nd. Finally, Sanford C. Bernstein restated a “market perform” rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Eleven investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $170.88.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock opened at $156.90 on Friday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The firm’s 50-day simple moving average is $153.84 and its 200-day simple moving average is $153.72. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The firm has a market cap of $377.52 billion, a P/E ratio of 23.59, a price-to-earnings-growth ratio of 2.56 and a beta of 0.42.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.59 by $0.18. The business had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. As a group, research analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were given a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, May 27th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a yield of 3.31%. Johnson & Johnson’s payout ratio is 57.84%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.